PHP
CALA

Parkman Healthcare Partners’s Calithera Biosciences, Inc CALA Stock Holding History

Parkman Healthcare Partners’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,031
Closed -$219K – 91
2021
Q3 		$219K Hold
5,031
– – 0.06% 74
2021
Q2 		$210K Buy
+5,031
New +$221K 0.05% 82

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Parkman Healthcare Partners's CALA Position: Q4 2021 in Review

Parkman Healthcare Partners sold out of Calithera Biosciences, Inc (CALA) in Q4 2021, closing a stake of 5,031 shares — an estimated $219K sold.

Parkman Healthcare Partners first reported a position in CALA in Q2 2021 and held it in 2 quarters. The position peaked at $219K in Q3 2021. 55 funds tracked by Wall St. Rank hold CALA as of Q4 2021.

  • Parkman Healthcare Partners reported no remaining Calithera Biosciences, Inc position as of Q4 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 5,031 Calithera Biosciences, Inc shares in Q4 2021, an estimated $219K.
  • Parkman Healthcare Partners first reported a position in Calithera Biosciences, Inc in Q2 2021 and held it in 2 quarters.
  • Parkman Healthcare Partners's Calithera Biosciences, Inc position peaked at $219K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2021.

Based on Parkman Healthcare Partners's 13F filing for Q4 2021, filed 11 Feb 2022.